Genetics

Tamoxifen Data Seen as A Boon for Gene Testing

Published in Gene Therapy Weekly, April 27th, 1998

Dramatic data showing the drug tamoxifen can prevent breast cancer is seen as likely to spur more women to seek tests that can identify defective genes linked to the disease, boosting prospects for two rival gene-testing companies, Wall Street analysts said.

But analysts and officials of the companies, Myriad Genetics Inc., Salt Lake City, Utah, and Oncormed Inc., Gaithersburg, Maryland, said that any increase in breast cancer gene screening is likely to be slow and steady rather than explosive because of a variety of factors.

They cited side effects from tamoxifen, steep costs of breast cancer gene tests and lingering societal distrust of genetic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry